Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas. Show more

Location: Building 14, Stafford, TX, 77477, United States | Website: https://greenwichlifesciences.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

152M

52 Wk Range

$8.06 - $15.50

Previous Close

$11.27

Open

$11.22

Volume

75,729

Day Range

$11.03 - $11.66

Enterprise Value

149.1M

Cash

3.125M

Avg Qtr Burn

-2.126M

Insider Ownership

51.30%

Institutional Own.

10.45%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GLSI-100 Details Breast cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.